Trials / Completed
CompletedNCT03964220
Impact of Tiotropium Add-on Therapy in Patients With Asthma
The Effectiveness of Tiotropium Add-on Therapy Using a Real-world Cohort of Patients With Asthma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,857 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium Respimat® | Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist ) |
| DRUG | Inhaled Corticosteroid/Long-acting beta-agonist | baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA |
Timeline
- Start date
- 2019-03-15
- Primary completion
- 2019-09-20
- Completion
- 2019-09-20
- First posted
- 2019-05-28
- Last updated
- 2020-11-03
- Results posted
- 2020-10-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03964220. Inclusion in this directory is not an endorsement.